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Abstract
Stress is associated with poorer physical and mental health. To improve our understanding of this link, we performed
genome-wide association studies (GWAS) of depressive symptoms and genome-wide by environment interaction
studies (GWEIS) of depressive symptoms and stressful life events (SLE) in two UK population-based cohorts (Generation
Scotland and UK Biobank). No SNP was individually signiﬁcant in either GWAS, but gene-based tests identiﬁed six
genes associated with depressive symptoms in UK Biobank (DCC, ACSS3, DRD2, STAG1, FOXP2 and KYNU; p < 2.77 ×
10−6). Two SNPs with genome-wide signiﬁcant GxE effects were identiﬁed by GWEIS in Generation Scotland:
rs12789145 (53-kb downstream PIWIL4; p= 4.95 × 10−9; total SLE) and rs17070072 (intronic to ZCCHC2; p= 1.46 ×
10−8; dependent SLE). A third locus upstream CYLC2 (rs12000047 and rs12005200, p < 2.00 × 10−8; dependent SLE)
when the joint effect of the SNP main and GxE effects was considered. GWEIS gene-based tests identiﬁed: MTNR1B
with GxE effect with dependent SLE in Generation Scotland; and PHF2 with the joint effect in UK Biobank (p < 2.77 ×
10−6). Polygenic risk scores (PRSs) analyses incorporating GxE effects improved the prediction of depressive symptom
scores, when using weights derived from either the UK Biobank GWAS of depressive symptoms (p= 0.01) or the PGC
GWAS of major depressive disorder (p= 5.91 × 10−3). Using an independent sample, PRS derived using GWEIS GxE
effects provided evidence of shared aetiologies between depressive symptoms and schizotypal personality, heart
disease and COPD. Further such studies are required and may result in improved treatments for depression and other
stress-related conditions.
Introduction
Mental illness results from the interplay between genetic
susceptibility and environmental risk factors1,2. Previous
studies have shown that the effects of environmental factors
on traits may be partially heritable3 and moderated by
genetics4,5. Major depressive disorder (MDD) is the most
common psychiatric disorder with a lifetime prevalence of
approximately 14% globally6 and with a heritability of
approximately 37%7. There is strong evidence for the role of
stressful life events (SLEs) as risk factor and trigger for
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depression8–12. Genetic control of sensitivity to stress may
vary between individuals, resulting in individual differences
in the depressogenic effects of SLE, i.e., genotype-by-
environment interaction (GxE)4,13–16. Signiﬁcant evidence
of GxE has been reported for common respiratory diseases
and some forms of cancer17–22, and GxE studies have
identiﬁed genetic risk variants not found by genome-wide
association studies (GWAS)23–27.
Interaction between polygenic risk of MDD and recent
SLE are reported to increase liability to depressive
symptoms4,16; validating the implementation of genome-
wide approaches to study GxE in depression. Most GxE
studies for MDD have been conducted on candidate
genes, or using polygenic approaches to a wide range of
environmental risk factors, with some contradictory
ﬁndings28–32. Incorporating knowledge about recent SLE
into GWAS may improve our ability to detect risk var-
iants in depression otherwise missed in GWAS33. To date,
three studies have performed genome-wide by environ-
ment interaction studies (GWEIS) of MDD and SLE34–36,
but this is the ﬁrst study to perform GWEIS of depressive
symptoms using adult SLE in cohorts of relatively
homogeneous European ancestry.
Interpretation of GxE effects may be hindered by
gene–environment correlation. Gene–environment cor-
relation denotes a genetic mediation of associations
through genetic inﬂuences on exposure to, or reporting
of, environments2,37. Genetic factors predisposing to
MDD may contribute to exposure and/or reporting of
SLE38. To tackle this limitation, measures of SLE can be
broken down into SLE likely to be independent of a
respondent’s own behaviour and symptoms, or into
dependent SLE, in which participants may play an active
role exposure to SLE39,40. Different genetic inﬂuences,
including a higher heritability, are reported for dependent
SLE compared to independent SLE38,41–44, suggesting that
whereas GxE driven by independent SLE is likely to reﬂect
a genetic moderation of associations between SLE and
depression, GxE driven by dependent SLE may result
from a genetic mediation of the association through
genetically driven personality or behavioural traits. To test
this, we analysed dependent and independent SLE scores
separately in Generation Scotland (GS).
Stress contributes to many human conditions, with
evidence of genetic vulnerability to the effect of SLE45.
Therefore, genetic stress-response factors in MDD may
also underlie the aetiology of other stress-linked disorders
with which MDD is often comorbid46,47 (e.g., cardiovas-
cular diseases48, diabetes49, chronic pain50 and inﬂam-
mation51). We tested the hypothesis that pleiotropy and
shared aetiology between mental and physical health
conditions may be due in part to genetic variants under-
lying SLE effects in depression.
In this study, we conduct GWEIS of depressive symp-
toms incorporating data on SLE in two independent UK-
based cohorts. We aimed to: (i) identify loci associated
with depressive symptoms through genetic response to
SLE; (ii) study dependent and independent SLE to support
a contribution of genetically mediated exposure to stress;
(iii) assess whether GxE effects improve the proportion of
phenotypic variance in depressive symptoms explained by
genetic additive main effects alone; and (iv) test for a
signiﬁcant overlap in the genetic aetiology of the response
to SLE and mental and physical stress-related phenotypes.
Materials and methods
The core workﬂow of this study is summarised in Fig. 1.
Cohort descriptions
GS
GS is a family-based population cohort representative of
the Scottish population52. At baseline, blood and salivary
DNA samples were collected, stored and genotyped at the
Wellcome Trust Clinical Research Facility, Edinburgh.
Genome-wide genotype data were generated using the
Illumina HumanOmniExpressExome-8 v1.0 DNA Analy-
sis BeadChip (San Diego, CA, USA) and Inﬁnium chem-
istry53. The procedures and details for DNA extraction
and genotyping have been extensively described else-
where54,55. In total, 21,525 participants were re-contacted
to participate in a follow-up mental health study (Strati-
fying Resilience and Depression Longitudinally,
STRADL), of which 8541 participants responded provid-
ing updated measures in psychiatric symptoms and SLE
through self-reported mental health questionnaires56.
Samples were excluded if: they were duplicate samples,
had diagnoses of bipolar disorder, no SLE data
(non-respondents), were population outliers (mainly non-
Caucasians and Italian ancestry subgroup), had sex mis-
matches or were missing >2% of genotypes. Single
nucleotide polymorphisms (SNPs) were excluded if:
missing >2% of genotypes, Hardy–Weinberg equilibrium
test p < 1 × 10−6, or minor allele frequency <1%. Further
details of the GS and STRADL cohort are available else-
where52,56–58. All components of GS and STRADL
obtained ethical approval from the Tayside Committee on
Medical Research Ethics on behalf of the NHS (reference
05/s1401/89). After quality control, individuals were ﬁl-
tered by degree of relatedness (pi-hat < 0.05), maximising
retention of those individuals reporting a higher number
of SLE. The ﬁnal dataset comprised data on 4919 unre-
lated individuals (1929 men; 2990 women) and 560,351
SNPs.
Independent GS datasets
Additional datasets for a range of stress-linked medical
conditions and personality traits were created from GS (N
Arnau-Soler et al. Translational Psychiatry            (2019) 9:14 Page 2 of 13
= 21,525) excluding respondents and their relatives (N=
5724). Following the same quality control criteria detailed
above, we maximised unrelated non-respondents for
retention of cases, or proxy cases (see below), to maximise
the information available for each phenotype. This
resulted in independent datasets with unrelated indivi-
duals for each trait. Differences between respondents and
non-respondents are noted in the ﬁgure legend of Table 1.
UK Biobank (UKB)
This study used data from 99,057 unrelated individuals
(47,558 men; 51,499 women) from the initial release of
UKB genotyped data (released 2015; under UKB project
4844). Brieﬂy, participants were removed based on UKB
genomic analysis exclusion, non-white British ancestry,
high missingness, genetic relatedness (kinship coefﬁcient
> 0.0442), QC failure in UK BiLEVE study and gender
mismatch. GS participants and their relatives were
excluded and GS SNPs imputed to a reference set com-
bining the UK10K haplotype and 1000 Genomes Phase 3
reference panels59. After quality control, 1,009,208 SNPs
remained. UKB received ethical approval from the NHS
National Research Ethics Service North West (reference:
11/NW/0382). Further details on UKB cohort description,
genotyping, imputation and quality control are available
elsewhere60–62.
All participants provided informed consent.
Phenotype assessment
SLEs
GS participants reported SLE experienced over the
preceding 6 months through a self-reported brief life
events questionnaire based on the 12-item list of threa-
tening experiences39,63,64 (Supplementary Table 1a). The
total number of SLE reported (TSLE) consisted of the
number of ‘yes’ responses. TSLE were subdivided into SLE
Fig. 1 Study ﬂowchart. Overview of the analyses conducted in this study: (i) identify loci associated with depressive symptoms through genetic
response to SLE; (ii) test whether results of studying dependent and independent SLE support a contribution of genetically mediated exposure to
stress; (iii) assess whether GxE effects improve the proportion of phenotypic variance in depressive symptoms explained by genetic additive main
effects alone and (iv) test whether there is signiﬁcant overlap in the genetic aetiology of the response to SLE and mental and physical stress-related
phenotypes. Two core cohorts are used, Generation Scotland (GS) and UK Biobank (UKB). Summary statistics from genome-wide association studies
(GWAS) and genome-wide by environment interaction studies (GWEIS) are used to generate polygenic risk scores (PRSs). Summary statistics from
Psychiatric Genetic Consortium (PGC) Major Depressive Disorder (MDD) GWAS are also used to generate PRS (PRSMDD). PRS weighted by: additive
effects (PRSD and PRSMDD), GxE effects (PRSGxE) and joint effects (the combined additive and GxE effect; PRSJoint), are used for phenotypic prediction.
TSLE stands for total number of SLE reported. DSLE stands for SLE dependent on an individual’s own behaviour. Conversely, ISLE stands for
independent SLE. N stands for sample size. NnoGS stands for sample size with GS individuals removed. NnoUKB stands for sample size with UKB
individuals removed
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potentially dependent or secondary to an individual’s own
behaviour (DSLE, questions 6–11 in Supplementary Table
1a), and independent SLE (ISLE, questions 1–5 in
Supplementary Table 1a; pregnancy item removed) fol-
lowing Brugha et al.39,40. Thus, three SLE measures
(TSLE, DSLE and ISLE) were constructed for GS. UKB
Table 1 GS samples with stress-related phenotypes
Trait N Males/females N SNPs N Cases N Controls
Alzheimer (R) 3377 1475/1903 560,622 655 2722
Asthma 3390 1500/1890 560,569 555 2835
Asthma (R) 3375 1470/1905 560,432 910 2465
Bowel cancer (R) 3386 1495/1891 560,630 672 2714
Breast cancer 3388 1486/1902 560,611 83 3305
Breast cancer (R) 3386 1482/1904 560,579 564 2822
Chronic obstructive pulmonary disease 3387 1496/1891 560,591 73 3314
Chronic obstructive pulmonary disease (R) 3387 1474/1913 560,620 553 2834
Depression 3385 1495/1890 560,584 483 2902
Depression (R) 3382 1506/1876 560,514 731 2651
Diabetes 3388 1497/1891 560,469 185 3203
Diabetes (R) 3389 1481/1908 560,584 1144 2245
Heart disease 3392 1504/1888 560,526 212 3180
Heart disease (R) 3377 1483/1894 560,479 2254 1123
High blood pressure 3402 1501/1901 560,508 729 2673
High blood pressure (R) 3372 1464/1908 560,569 1901 1471
Hip fracture (R) 3388 1489/1899 560,572 421 2967
Lung cancer (R) 3379 1492/1887 560,600 798 2581
Osteoarthritis 3395 1486/1909 560,640 411 2984
Osteoarthritis (R) 3383 1466/1917 560,516 961 2422
Parkinson (R) 3388 1488/1900 560,590 236 3152
Prostate cancer (R) 3381 1495/1886 560,570 329 3052
Rheumatoid arthritis 3387 1490/1897 560,618 93 3294
Rheumatoid arthritis (R) 3380 1487/1893 560,543 765 2615
Stroke 3387 1492/1895 560,613 81 3306
Stroke (R) 3385 1463/1922 560,478 1506 1879
Neuroticisma 3421 1521/1900 560,484 - -
Extraversiona 3420 1520/1900 560,476 - -
Schizotypal personalitya 2386 1065/1321 560,369 - -
Mood disordera 2307 1040/1267 560,318 - -
Samples were maximised for retention of cases to maximise the information available for each trait. There was no preferential selection of relatives in pairs for
quantitative phenotypes, in order to retain the underlying distribution. All individuals involved in the datasets listed above were non-respondents to the GS follow-up
study. Compared with individuals included at GS GWEIS (respondents in GS follow-up), non-respondents were signiﬁcantly: younger, from more socioeconomically
deprived areas, generally less healthier and wealthier. Non-respondents were more likely to smoke, and less likely to drink alcohol, although they consumed more
units per week, compared with respondents. At GS baseline, non-respondents experienced more psychological distress and reported higher scores in symptoms of
GHQ-depression and GHQ-anxiety than respondents56
The total target sample size (N), number of males and females in N, number of SNPs (N SNPs) in target sample size N: the number of SNPs used as predictors after
clumping step range between 90,650 and 91,000. The number of cases and controls in the independent target sample is indicated for binary phenotypes only.
Samples were mapping by proxy approach was used (i.e., where ﬁrst-degree relatives of individuals with the disease were considered proxy cases and included into
the group of cases) are indicated by (R)
GS Generation Scotland, GWEIS genome-wide by environment interaction studies, GHQ General Health Questionnaire
aAssessed through self-reported questionnaires
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participants were screened for ‘illness, injury, bereave-
ment and stress’’ (Supplementary Table 1b) over the
previous 2 years using six items included in the UKB
Touchscreen questionnaire. A score reﬂecting SLE
reported in UKB (TSLEUKB) was constructed by summing
the number of ‘yes’ responses.
Psychological assessment
GS participants reported whether their current mental
state over the preceding 2 weeks differed from their
typical state using a self-administered 28-item scaled
version of the General Health Questionnaire (GHQ)65–67.
Participants rated the degree and severity of their current
symptoms with a four-point Likert scale (following
Goldberg et al.67). A ﬁnal log-transformed GHQ was used
to detect altered psychopathology and thus, assess
depressive symptoms as results of SLE. In UKB partici-
pants, current depressive symptoms over the preceding
2 weeks were evaluated using four psychometric screening
items (Supplementary Table 2), including two validated
and reliable questions for screening depression68, from
the Patient Health Questionnaire (PHQ) validated to
screen mental illness69,70. Each question was rated in a
four-point Likert scale to assess impairment/severity of
symptoms. Due to its skewed distribution, a four-point
PHQ score was formed from PHQ (0= 0; 1= 1–2; 2=
3–5; 3= 6 or more) to create a more normal distribution.
Stress-related traits
Targeted GS stress-related phenotypes and sample sizes
are shown in Table 1 and detailed elsewhere52. These
conditions were selected from literature review based on
previous evidence of a link with stress45 (see also Sup-
plementary Material: third section). Furthermore, we
created additional independent samples using mapping by
proxy, where individuals with a self-reported ﬁrst-degree
relative with a selected phenotype were included as proxy
cases. This approach provides greater power to detect
susceptibility variants in traits with low prevalence71.
Statistical analyses
SNP-heritability and genetic correlation
A restricted maximum likelihood approach was applied
to estimate SNP-heritability (h2SNP) of depressive symp-
toms and self-reported SLE measures, and within samples
bivariate genetic correlation between depressive symp-
toms and SLE measures using GCTA72.
GWAS analyses
GWAS were conducted in PLINK73. In GS, age, sex and
20 principal components (PCs) were ﬁtted as covariates.
In UKB, age, sex and 15 PCs recommended by UKB were
ﬁtted as covariates. The genome-wide signiﬁcance
threshold was p= 5 × 10–8.
GWEIS analyses
GWEIS were conducted on GHQ (the dependent vari-
able) for TSLE, DSLE and ISLE in GS and on PHQ for
TSLEUKB in UKB ﬁtting the same covariates
detailed above to reduce error variance. GWEIS were
conducted using an R plugin for PLINK73 developed by
Almli et al.74 (https://epstein-software.github.io/robust-
joint-interaction). This method implements a robust test
that jointly considers SNP and SNP–environment inter-
action effects from a full model (Y ~ β0+ βSNP+ βSLE+
βSNPxSLE+ βCovariates) against a null model where
both the SNP and SNP×SLE effects equal 0, to assess the
joint effect (the combined additive main and GxE genetic
effect at a SNP) using a nonlinear statistical approach that
applies Huber–White estimates of variance to correct
possible inﬂation due to heteroscedasticity (unequal var-
iances across exposure levels). This robust test should
reduce confounding due to differences in variance
induced by covariate interaction effects if present75.
Additional code was added (courtesy of Prof. Michael
Epstein;74 Supplementary Material) to generate beta-
coefﬁcients and the p-value of the GxE term alone. In
UKB, correcting for 1,009,208 SNPs and one exposure, we
established a Bonferroni-adjusted threshold for sig-
niﬁcance at p= 2.47 × 10–8 for both joint and GxE effects.
In GS, correcting for 560,351 SNPs and three measures of
SLE we established a genome-wide signiﬁcance threshold
of p= 2.97 × 10–8.
Post-GWAS/GWEIS analyses
GWAS and GWEIS summary statistics were analysed
using FUMA76 including: gene-based tests, functional
annotation, gene prioritisation and pathway enrichment
(Supplementary Material).
Polygenic proﬁling and prediction
Polygenic risk scores (PRSs) weighting by GxE effects
(PRSGxE) were generated using PRSice-2
77 (Supplemen-
tary Material) in GS using GxE effects from UKB-GWEIS.
In UKB, PRSGxE were constructed using GxE effects from
all three GS-GWEIS (TSLE, DSLE and ISLE as exposures)
independently. PRS were also weighted in both samples
using either UKB-GWAS or GS-GWAS statistics (PRSD),
and summary statistics from Psychiatric Genetic Con-
sortium (PGC) MDD-GWAS (released 2016; PRSMDD)
that excluded GS and UKB individuals when required
(NnoGS= 155,866; NnoUKB= 138,884). Furthermore, we
calculated PRS weighted by the joint effects (the com-
bined additive main and GxE genetic effects; PRSJoint)
from either the UKB-GWEIS or GS-GWEIS. PRS pre-
dictions of depressive symptoms were permuted 10,000
times. Multiple regression models ﬁtting PRSGxE and
PRSMDD, and both PRSGxE and PRSD were tested. All
models were adjusted by same covariates used in GWAS/
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GWEIS. Null models were estimated from the direct
effects of covariates alone. The predictive improvement of
combining PRSGxE and PRSMDD/PRSD effects over
PRSMDD/PRSD effects alone was tested for signiﬁcance
using the likelihood ratio test (LRT).
Prediction of PRSD, PRSGxE and PRSJoint of stress-linked
traits were adjusted by age, sex and 20 PCs; and permuted
10,000 times. Empirical-p-values after permutations were
further adjusted by false discovery rate (FDR, conservative
threshold at Empirical-p= 6.16 × 10–3). The predictive
improvement of ﬁtting PRSGxE combined with PRSD and
covariates over prediction of a phenotype using the PRSD
effect alone with covariates was assessed using LRT, and
LRT-p-values adjusted by FDR (conservative threshold at
LRT-p= 8.35 × 10–4).
Results
Phenotypic and genetic correlations
Depressive symptom scores and SLE measures were
positively correlated in both UKB (r2= 0.22, p < 2.2 ×
10–16) and GS (TSLE-r2= 0.21, p= 1.69 × 10−52; DSLE-r2
= 0.21, p= 8.59 × 10−51; ISLE-r2= 0.17, p= 2.33 ×
10−33). Signiﬁcant bivariate genetic correlation between
depression and SLE scores was identiﬁed in UKB (rG=
0.72; p < 1 × 10−5, N= 50,000), but not in GS (rG= 1, p=
0.056, N= 4919; Supplementary Table 3a).
SNP-heritability (h2SNP)
In UKB, a signiﬁcant h2SNP of PHQ was identiﬁed
(h2SNP= 0.090; p < 0.001; N= 99,057). This estimate
remained signiﬁcant after adjusting by TSLEUKB effect
(h2SNP= 0.079; p < 0.001), suggesting a genetic contribu-
tion unique to depressive symptoms. The h2SNP of
TSLEUKB was also signiﬁcant (h
2
SNP= 0.040, p < 0.001;
Supplementary Table 3b). In GS, h2SNP was not signiﬁcant
for GHQ (h2SNP= 0.071, p= 0.165; N= 4919). However,
in an ad hoc estimation from the baseline sample of 6751
unrelated GS participants (details in Supplementary Table
3b) we detected a signiﬁcant h2SNP for GHQ (h
2
SNP=
0.135; p < 5.15 × 10−3), suggesting that the power to esti-
mate h2SNP in GS may be limited by sample size. Estimates
were not signiﬁcant for either TSLE (h2SNP= 0.061, p=
0.189; Supplementary Table 3b) or ISLE (h2SNP= 0.000, p
= 0.5), but h2SNP was signiﬁcant for DSLE (h
2
SNP= 0.131,
p= 0.029), supporting a potential genetic mediation and
gene–environment correlation.
GWAS of depressive symptoms
No genome-wide signiﬁcant SNPs were detected by
GWAS in either cohort. Top ﬁndings (p < 1 × 10−5)
are summarised in Supplementary Table 4. Manhattan
and QQ plots are shown in Supplementary Figures 1-4.
There was no evidence of genomic inﬂation
(all λ1000 < 1.01).
Post-GWAS analyses
Gene-based test identiﬁed six genes associated with
PHQ using the UKB-GWAS statistics at genome-wide
signiﬁcance (Bonferroni-corrected p= 2.77 × 10−6; DCC,
p= 7.53 × 10−8; ACSS3, p= 6.51 × 10−7; DRD2, p=
6.55 × 10−7; STAG1, p= 1.63 × 10−6; FOXP2, p= 2.09 ×
10−6; KYNU, p= 2.24 × 10−6; Supplementary Figure 8).
Prioritised genes based on position, expression quantita-
tive trait loci (eQTL) and chromatin interaction mapping
are detailed in Supplementary Table 5. No genes were
detected in GS-GWAS gene-based test (Supplementary
Figures 9). No tissue-speciﬁc enrichment was detected
from GWAS in either cohort. Signiﬁcant gene-sets and
GWAS catalogue associations for UKB-GWAS are
reported in Supplementary Table 6. These included the
biological process: positive regulation of long-term
synaptic potentiation, and GWAS catalogue associations:
brain structure, schizophrenia, response to ampheta-
mines, age-related cataracts (age at onset), ﬁbrinogen,
acne (severe), ﬁbrinogen levels and educational attain-
ment; all adjusted-p < 0.01. There was no signiﬁcant gene-
set enrichment from GS-GWAS.
GWEIS of depressive symptoms
Manhattan and QQ plots are shown in Supplementary
Figures 1-4. There was no evidence of GWEIS inﬂation
for either UKB or GS (all λ1000 < 1.01). No genome-wide
signiﬁcant GWEIS associations were detected for SLE in
UKB. GS-GWEIS using TSLE identiﬁed a signiﬁcant GxE
effect (p < 2.97 × 10−8) at an intragenic SNP on chromo-
some 11 (rs12789145, p= 4.95 × 10−9, β= 0.06, closest
gene: PIWIL4; Supplementary Figure 5), and using DSLE
at an intronic SNP in ZCCHC2 on chromosome 18
(rs17070072, p= 1.46 × 10−8, β=−0.08; Supplementary
Figure 6). In their corresponding joint effect tests, both
rs12789145 (p= 2.77 × 10−8) and rs17070072 p= 1.96 ×
10−8) were signiﬁcant. GWEIS for joint effect using DSLE
identiﬁed two further signiﬁcant SNPs on chromosome 9
(rs12000047, p= 2.00 × 10−8, β=−0.23; rs12005200, p=
2.09 × 10−8, β=−0.23, LD r2 > 0.8, closest gene: CYLC2;
Supplementary Figure 7). None of these associations
replicated in UKB (p > 0.05), although the effect direction
was consistent between cohorts for the SNP close to
PIWL1 and SNPs at CYLC2. No SNP achieved genome-
wide signiﬁcant association in the GS-GWEIS using ISLE
as exposure. Top GWEIS results (p < 1 × 10−5) are sum-
marised in Supplementary Tables 7-10.
Post-GWEIS analyses: gene-based tests
All results are shown in Supplementary Figures 10-17.
Two genes were associated with PHQ using the joint
effect from the UKB-GWEIS (ACSS3 p= 1.61 × 10−6;
PHF2, p= 2.28 × 10−6; Supplementary Figure 11). ACSS3
was previously identiﬁed using the additive main effects,
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whereas PHF2 was only signiﬁcantly associated using the
joint effects. Gene-based tests identiﬁed MTNR1B as
signiﬁcantly associated with GHQ on the GS-GWEIS
using DSLE in both GxE (p= 1.53 × 10−6) and joint
effects (p= 2.38 × 10−6; Supplementary Figures 14-15).
Post-GWEIS analyses: tissue enrichment
We prioritised genes based on position, eQTL and
chromatin interaction mapping in brain tissues and
regions. In UKB, prioritised genes using GxE effects were
enriched for upregulated differentially expressed genes
from adrenal gland (adjusted-p= 3.58 × 10−2). Using joint
effects, prioritised genes were enriched on upregulated
differentially expressed genes from artery tibial (adjusted-
p= 4.34 × 10−2). In GS, prioritised genes were enriched:
in upregulated differentially expressed genes from artery
coronary (adjusted-p= 4.55 × 10−2) using GxE effects
with DSLE; in downregulated differentially expressed
genes from artery aorta tissue (adjusted-p= 4.71 × 10−2)
using GxE effects with ISLE; in upregulated differentially
expressed genes from artery coronary (adjusted-p=
5.97 × 10−3, adjusted-p= 9.57 × 10−3) and artery tibial
(adjusted-p= 1.05 × 10−2, adjusted-p= 1.55 × 10−2) tis-
sues using joint effects with both TSLE and DSLE; and in
downregulated differentially expressed genes from lung
tissue (adjusted-p= 3.98 × 10−2) and in up- and down-
regulated differentially expressed genes from the spleen
(adjusted-p= 4.71 × 10−2) using joint effects with ISLE.
There was no enrichment using GxE effect with TSLE.
Post-GWEIS analyses: gene-sets enrichment
Signiﬁcant gene-sets and GWAS catalogue hits from
GWEIS are detailed in Supplementary Tables 11-14,
including for UKB Biocarta: GPCR pathway; Reactome:
opioid signalling, neurotransmitter receptor binding and
downstream transmission in the postsynaptic cell, trans-
mission across chemical synapses, gastrin CREB signalling
pathway via PKC and MAPK; GWAS catalogue: post
bronchodilator FEV1/FVC ratio, migraine and body mass
index. In GS, enrichment was seen using TSLE and DLSE
for GWAS catalogue: age-related macular degeneration,
myopia, urate levels and Heschl’s gyrus morphology; and
using ISLE for biological process: regulation of transporter
activity. All adjusted-p < 0.01.
Cross-cohort prediction
In GS, PRSD weighted by the UKB-GWAS of PHQ
signiﬁcantly explained 0.56% of GHQ variance (Empirical-
p < 1.10−4), similar to PRSMDD weighted by PGC MDD-
GWAS (R2= 0.78%, Empirical-p < 1.10−4). PRSGxE
weighted by the UKB-GWEIS GxE effects explained
0.15% of GHQ variance (Empirical-p= 0.03, Supplemen-
tary Table 15). PRSGxE ﬁtted jointly with PRSMDD sig-
niﬁcantly improved prediction of GHQ (R2= 0.93%,
model p= 6.12 × 10−11; predictive improvement of 19%,
LRT-p= 5.91 × 10−3) compared with PRSMDD alone.
Similar to PRSGxE with PRSD (R
2= 0.69%, model p=
2.72 × 10−8; predictive improvement of 23%, LRT-p=
0.01). PRSJoint weighted by the UKB-GWEIS also pre-
dicted GHQ (R2= 0.58%, Empirical-p < 1.10−4), although
Fig. 2 Prediction of depression scores by PRSGxE, PRSD, PRSMDD
and PRSJoint. Variance of depression score explained by PRSGxE PRSD,
PRSMDD and PRSJoint as single effect; and combining both PRSD and
PRSMDD with PRSGxE in single models. Prediction was conducted using
a Generation Scotland (GS) and b UK Biobank (UKB) as target sample.
PRSGxE were weighted by cross- sample genome-wide by
environment interaction studies (GWEIS) using GxE effect. PRSD were
weighted by cross-sample genome-wide association studies (GWAS)
of depressive symptoms effect. PRSMDD was weighted by Psychiatric
Genetic Consortium (PGC) Major Depressive Disorder (MDD)-GWAS
summary statistics. PRSJoint were weighted by cross-sample GWEIS
using joint effect. A nominally signiﬁcant gain in variance explained of
General Health Questionnaire (GHQ) of about 23% was seen in GS
when PRSGxE was incorporated into a multiple regression model along
with PRSD; and of about 19% when PRSGxE was incorporated into a
multiple regression model along with PRSMDD. Such a gain was not
seen in UKB, but it must be noted that both PRSD and PRSMDD also
explains much less variance of PHQ in UKB than of GHQ in GS. Also
note, a noticeably reduction of variance explained by PRSJoint
compared with combined polygenic risk scores (PRS)/effects
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the variance explained was signiﬁcantly reduced com-
pared with the model ﬁtting PRSGxE and PRSD together
(LRT-p= 4.69 × 10−7), suggesting that additive and GxE
effects should be modelled independently for polygenic
approaches (Fig. 2a).
In UKB (Fig. 2b), both PRSD weighted by the GS-GWAS
of GHQ and PRSMDD signiﬁcantly explained 0.04 and
0.45% of PHQ variance, respectively (both Empirical-p <
1.10−4; Supplementary Table 15). PRSGxE derived from
the GS-GWEIS GxE effect did not signiﬁcantly predicted
PHQ (TSLE-PRSGxE Empirical-p= 0.382; DSLE-PRSGxE
Empirical-p= 0.642; ISLE-PRSGxE Empirical-p= 0.748).
Predictive improvements using the PRSGxE effect ﬁtted
jointly with PRSMDD or PRSD were not signiﬁcant (all
LRT-p > 0.08). PRSJoint signiﬁcantly predicted PHQ
(TSLE-PRSJoint: R
2= 0.032%, Empirical-p < 1.10−4; DSLE-
PRSJoint: R
2= 0.012%, Empirical-p= 4.3 × 10−3; ISLE-
PRSJoint: R
2= 0.032%, Empirical-p < 1.10−4), although
the variance explained was signiﬁcantly reduced com-
pared with the models ﬁtting PRSGxE and PRSD together
(all LRT-p < 1.48 × 10−3).
Prediction of stress-related traits
Prediction of stress-related traits in independent sam-
ples using PRSD, PRSGxE and PRSJoint are summarised in
Fig. 3a and Supplementary Table 16. Signiﬁcant trait
prediction after FDR adjustment (Empirical-p < 6.16 ×
10−3, FDR-adjusted Empirical-p < 0.05) using both UKB
and GS PRSD was seen for: depression status, neuroticism
and schizotypal personality. PRSGxE weighted by the GS-
GWEIS GxE effect using ISLE signiﬁcantly predicted
depression status mapped by proxy (Empirical-p= 7.00 ×
10−4, FDR-adjusted Empirical-p= 9.54 × 10−3).
Nominally signiﬁcant predictive improvements (LRT-p
< 0.05) of ﬁtting PRSGxE, over the PRSD effect alone, using
summary statistics generated from both UKB and GS
were detected for schizotypal personality, heart diseases
and chronic obstructive pulmonary disease (COPD) by
proxy (Fig. 3b). PRSGxE weighted by GS-GWEIS GxE
effect using ISLE signiﬁcantly improved prediction over
PRSD effect alone of depression status mapped by proxy
after FDR adjustment (LRT-p= 1.96 × 10−4, FDR-
adjusted LRT-p= 2.35 × 10−2).
Discussion
This study performs GWAS and incorporates data on
recent adult SLEs into GWEIS of depressive symptoms,
identiﬁes new loci and candidate genes for the modulation
of genetic response to SLE; and provides insights to help
disentangle the underlying aetiological mechanisms
increasing the genetic liability through SLE to both
depressive symptoms and stress-related traits.
SNP-heritability of depressive symptoms (h2SNP=
9–13%), were slightly higher than previous estimates from
African-American populations34, and over a third larger
than estimates in MDD from European samples78. h2SNP
for PHQ in UKB (9.0%) remained signiﬁcant after
adjusting for SLE (7.9%). Thus, although some genetic
contributions may be partially shared between depressive
symptoms and reporting of SLE, there is still a relatively
large genetic contribution unique to depressive symp-
toms. Signiﬁcant h2SNP of DSLE in GS (13%) and TSLEUKB
in UKB (4%), which is mainly composed of dependent SLE
items, were detected similar to previous studies (8 and
29%)34,42. Conversely, there was no evidence for herit-
ability of independent SLE. A signiﬁcant bivariate genetic
correlation between depressive symptoms and SLE (rG=
0.72) was detected in UKB after adjusting for covariates,
suggesting that there are shared common variants
underlying self-reported depressive symptoms and SLE.
This bivariate genetic correlation was smaller than that
estimated from African-American populations (rG= 0.97;
p= 0.04; N= 7179)34. Genetic correlations between SLE
measures and GHQ were not signiﬁcant in GS (N= 4919;
rG= 1; all p > 0.056), perhaps due to a lack of power in
this smaller sample.
Post-GWAS gene-based tests detected six genes sig-
niﬁcantly associated with PHQ (DCC, ACSS3, DRD2,
STAG1, FOXP2 and KYNU). Previous studies have
implicated these genes in liability to depression (see
Supplementary Table 17), and three of them are genome-
wide signiﬁcant in gene-based tests from the latest meta-
analysis of major depression that includes UKB (DCC, p
= 2.57 × 10−14; DRD2, p= 5.35 × 10−14; and KYNU, p=
2.38 × 10−6; N= 807,553)79. This supports the imple-
mentation of quantitative measures such as PHQ to detect
genes underlying lifetime depression status80. For exam-
ple, signiﬁcant gene ontology analysis of the UKB-GWAS
identiﬁed enrichment for positive regulation of long-term
synaptic potentiation, and for previous GWAS ﬁndings of
brain structure81, schizophrenia82 and response to
amphetamines83.
The key element of this study was to conduct GWEIS of
depressive symptoms and recent SLE. We identiﬁed two
loci with signiﬁcant GxE effect in GS. However, none of
these associations replicated in UKB (p > 0.05). The
strongest association was using TSLE at 53-kb down-
stream of PIWIL4 (rs12789145). PIWIL4 is brain expres-
sed and involved in chromatin modiﬁcation84, suggesting
it may moderate the effects of stress on depression. It
encodes HIWI2, a protein thought to regulate OTX2, that
is critical for the development of forebrain and for coor-
dinating critical periods of plasticity disrupting the inte-
gration of cortical circuits85,86. Indeed, an intronic SNP in
PIWIL4 was identiﬁed as the strongest GxE signal in
attention deﬁcit hyperactivity disorder using mother’s
warmth as environmental exposure87. The other sig-
niﬁcant GxE identiﬁed in our study was in ZCCHC2 using
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DSLE. This zinc-ﬁnger protein is expressed in blood CD4
+ T cells and is downregulated in individuals with MDD88
and in those resistant to treatment with citalopram89. No
GxE effect was seen using ISLE as exposure.
No signiﬁcant locus or gene with GxE effect was
detected in the UKB-GWEIS. Nevertheless, joint effects
(the combined additive main and GxE genetic effects)
identiﬁed two genes signiﬁcantly associated with PHQ
(ACSS3 and PHF2; see Supplementary Table 17). PHF2
was recently detected as genome-wide signiﬁcant at the
latest meta-analysis of depression79. Notably, PHF2
paralogs have previously been linked with MDD through
stress-response in three other studies90–92. Joint effects
analyses in GS also detected an additional signiﬁcant
association upstream CYLC2, a gene nominally associated
(p < 1 × 10−5) with obsessive-compulsive disorder
and Tourette’s syndrome93. Gene-based test from the
GS-GWEIS identiﬁed a signiﬁcant association with
Fig. 3 Polygenic risk score (PRS) prediction in independent Generation Scotland (GS) datasets. a Heatmap illustrating PRS prediction of a wide
range of traits from GS listed in the x axis (Table 1). (R) refers to traits using mapping by proxy approach (i.e., where ﬁrst-degree relatives of individuals
with the disease are considered proxy cases and included into the group of cases). Y axis shows the discovery sample and the effect used to weight
PRS. Numbers in cells indicate the % of variance explained, also represented by colour scale. Signiﬁcance is represented by asterixes according to the
following signiﬁcance codes: **p < 0.01; *p < 0.05; in grey Empirical-p-values after permutation (10,000 times) and in yellow FDR-adjusted Empirical-p-
values. b Predictive improvement by GxE effect in independent GS datasets. Heatmap illustrating the predictive improvement as a result of
incorporating PRSGxE into a multiple model along with PRSD and covariates (full model), over a model ﬁtting PRSD alone with covariates (null model);
predicting a wide range of traits from GS listed in the x axis (Table 1). Covariates: age, sex and 20 PCs. (R) refers to traits using mapping by proxy
approach (i.e., where ﬁrst-degree relatives of individuals with the disease are consider proxy cases and included into the group of cases). PRSGxE are
weighted by genome-wide by environment interaction studies (GWEIS) using GxE effects. PRSD were weighted by the genome-wide association
studies (GWAS) of depressive symptoms additive main effects. The y axis shows the discovery sample used to weight PRS. Numbers in cells indicate
the % of variance explained by the PRSGxE, also represented by colour scale. Notice that those correspond to the PRSGxE predictions in Fig. 3a when
PRSGxE are weighted by GxE effects. Signiﬁcance was tested by likelihood ratio tests (LRT): full model including PRSD+ PRSGxE vs. null model with
PRSD alone (covariates adjusted). Signiﬁcance is represented by asterixes according to the following signiﬁcance codes: ***p < 0.001; **p < 0.01; *p <
0.05; in grey LRT-p-values and in yellow FDR-adjusted LRT-p-values
Arnau-Soler et al. Translational Psychiatry            (2019) 9:14 Page 9 of 13
MTNR1B, a melatonin receptor gene, using DSLE (both
GxE and joint effect; Supplementary Table 17). Genes
prioritised using GxE effects were enriched in differen-
tially expressed genes from several tissues including the
adrenal gland, which releases cortisol into the blood-
stream in response to stress, thus playing a key role in the
stress-response system, reinforcing a potential role of GxE
in stress-related conditions.
The different instruments and sample sizes available
make it hard to compare results between cohorts.
Whereas GS contains deeper phenotyping measurements
of stress and depressive symptoms than UKB, the sample
size is much smaller, which may be reﬂected in the sta-
tistical power required to reliably detect GxE effects.
Furthermore, the presence and size of GxE effects are
dependent on their parameterisation (i.e., the measure-
ment, scale and distribution of the instruments used to
test such interaction)94. Thus, GxE may be incomparable
across GWEIS due to differences in both phenotype
assessment and stressors tested. Although our results
suggest that both depressive symptom measures are cor-
related with lifetime depression status, different inﬂuences
on depressive symptoms from the SLE covered across
studies may contribute to lack of stronger replication.
Instruments in GS cover a wider range of SLE and are
more likely to capture changes in depressive symptoms as
consequence of their short-term effects. Conversely, UKB
could capture more marked long-term effects, as SLE
were captured over 2 years compared with the 6 months
in GS. New mental health questionnaires covering a wide
range of psychiatric symptoms and SLE in the latest
release of UKB data provides the opportunity to create
similar measures to GS in the near future. Further repli-
cation in independent studies with equivalent instruments
is required to validate our GWEIS ﬁndings. Despite these
limitations and a lack of overlap in the individual genes
prioritised from the two GWEIS, replication was seen in
the predictive improvement of using PRSGxE derived from
the GWEIS GxE effects to predict stress-related
phenotypes.
The third aim of this study was to test whether mod-
elling GxE effects could improve predictive genetic
models, and thus help to explain deviation from additive
models and missing heritability for MDD95. Multiple
regression models suggested that inclusion of PRSGxE
weighted by GxE effects could improve prediction of an
individual’s depressive symptoms over use of PRSMDD or
PRSD weighted by additive effects alone. In GS, we
detected a predictive gain of 19% over PRSMDD weighted
by PGC MDD-GWAS, and a gain of 23% over PRSD
weighted by UKB-GWAS (Fig. 2a). However, these ﬁnd-
ings did not surpass stringent Bonferroni correction and
could not be validated in UKB. This may reﬂect in the
poor predictive power of the PRS generated from the
much smaller GS discovery sample. The results show a
noticeably reduced prediction using PRSJoint weighted by
joint effects, which suggests that the genetic architecture
of stress-response is at least partially independent and
differs from genetic additive main effects. Overall, our
results from multiple regression models suggest that for
polygenic approaches main and GxE effects should be
modelled independently.
SLE effects are not limited to mental illness45. Our ﬁnal
aim was to investigate shared aetiology between GxE for
depressive symptoms and stress-related traits. Despite the
differences between the respondents and non-
respondents (Table 1 legend), a signiﬁcant improvement
was seen in predicting depressive status when mapping by
proxy cases using GxE effect from GS-GWEIS with
independent SLE (FDR-adjusted LRT-p= 0.013), but not
with dependent SLE. GxE effects using statistics generated
from both discovery samples, despite the differences in
measures, nominally improved the phenotypic prediction
of schizotypal personality, heart disease and the proxy of
COPD (LRT-p < 0.05). Other studies have also found
evidence supporting a link between stress and depression
in these phenotypes (see Supplementary Material for
extended review) and suggest, for instance, potential
pleiotropy between schizotypal personality and stress-
response. Our ﬁndings point to a potential genetic com-
ponent underlying a stress-response-depression-
comorbidities link due, at least in part, to shared stress-
response mechanisms. A relationship between SLE,
depression and coping strategies such as smoking sug-
gests that genetic stress-response may modulate adaptive
behaviours such as smoking, fatty diet intake, alcohol
consumption and substance abuse. This is discussed fur-
ther in the Supplementary Material.
In this study, evidence for SNPs with signiﬁcant GxE
effects came primarily from the analyses of dependent
SLE and not from independent SLE. This supports a
genetic effect on probability of exposure to, or reporting
of SLE, endorsing a gene–environment correlation.
Chronic stress may inﬂuence cognition, decision making
and behaviour eventually leading to higher risk taking96.
These conditions may also increase sensitivity to stress
among vulnerable individuals, including those with
depression, who also have a higher propensity to report
SLE, particularly dependent SLE38. A potential reporting
bias in dependent SLE may be mediated as well by heri-
table behavioural, anxiety or psychological traits such as
risk taking42,97. Furthermore, individuals vulnerable to
MDD may behave in a manner that exposes them more
frequently to high risk and stressful environments14. This
complex interplay, reﬂected in the form of a
gene–environment correlation effect, would hinder the
interpretation of GxE effects from GWEIS as pure inter-
actions. A mediation of associations between SLE and
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depressive symptoms, through genetically driven sensi-
tivity to stress, personality or behavioural traits would
support the possibility of subtle genotype-by-genotype
(GxG) interactions, or genotype-by-genotype-by-envir-
onment (GxGxE) interactions, contributing to depres-
sion98,99. In contrast, PRS prediction of the stress-related
traits: schizotypal personality, heart disease and COPD,
was primarily from derived weights using independent
SLE, suggesting that a common set of variants moderate
the effects of SLE across stress-related traits and that
larger sample sizes will be required to detect the indivi-
dual SNPs contributing to this. Thus, our ﬁndings support
the inclusion of environmental information into GWAS
to enhance the detection of relevant genes. The results of
studying dependent and independent SLE support a
contribution of genetically mediated exposure to and/or
reporting of SLE, perhaps through sensitivity to stress as
mediator.
This study emphasises the relevance of GxE in depres-
sion and human health in general and provides the basis
for future lines of research.
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